

## **SMS Lifesciences India Limited**

Registered & Corporate Office : Plot No. 19-III, Road No. 71, Opp. Bharatiya Vidya Bhavan Public School, Jubilee Hills, Hyderabad - 500 096, Telangana, INDIA. Tel : +91-040-6628 8888, Fax : +91-40-2355 1401 CIN : L74930TG2006PLC050223 Email : info@smslife.in, Website : www.smslife.in

May 9, 2025

To **BSE Limited**, Listing Department, P J Towers, Dalal Street, Mumbai – 400 001. <u>Scrip Code</u>: **540679** 

National Stock Exchange of India Limited, Listing Department, "Exchange Plaza", Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051. <u>Trading Symbol</u>: SMSLIFE

Through: BSE Listing Center

Through: NEAPS Portal

## SUB: UPDATE ON "US-FDA" INSPECTION.

Ref: Regulation 30 (6) read with sub-para 20 of para "A" of part "A" of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

We are glad to inform that <u>United States Food and Drug Administration (USFDA)</u> has completed an inspection of the Company at its API manufacturing facility located at Sy. No. 180/2, Kazipally (V) Jinnaram Mandal, Sanga Reddy Dist. 502319, Telangana (Unit -1), from 5<sup>th</sup> May, 2025 to 9<sup>th</sup> May, 2025, with one observation. (**Annexure-1**).

Please note that final approval (EIR) is expected after submission of formal response to USFDA.

Kindly take the same on record and suitably disseminate it to all concerned.

## For SMS Lifesciences India Limited

Trupti Ranjan Mohanty Company Secretary



<u>SI No.</u>	Particulars	Information
1)	Name of the authority.	United States Food and Drug
		Administration (US FDA)
2)	Nature and details of the action(s)	1 (one) observation in Form 483.
	taken, initiated or order(s) passed.	The observation is procedural in nature and does
		not relate to data integrity or product quality.
3)	Date of receipt of direction or order,	May 9, 2025
	including any ad-interim or interim	
	orders, or any other communication	
	from the authority.	
4)	Details of the violation(s) /	Not Applicable
	contravention(s) committed or alleged	
	to be committed.	
5)	Impact on financial, operation or other	There is no impact on financial,
	activities of the Company, quantifiable	operations or other activities of the
	in monetary terms to the extent possible.	Company pursuant to the observation.

Details as specified in SEBI master circular dated November 11, 2024.

## \*\*\*\*

